Premium
The Continuous Glucose Monitoring System (CGMS) in type 1 diabetic children is the way to reduce hypoglycemic risk
Author(s) -
Schiaffini R.,
Ciampalini P.,
Fierabracci A.,
Spera S.,
Borrelli P.,
Bottazzo G. F.,
Crinò A.
Publication year - 2002
Publication title -
diabetes/metabolism research and reviews
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.307
H-Index - 110
eISSN - 1520-7560
pISSN - 1520-7552
DOI - 10.1002/dmrr.309
Subject(s) - medicine , fructosamine , hypoglycemia , continuous glucose monitoring , insulin , asymptomatic , type 1 diabetes , diabetes mellitus , glycemic , glycated hemoglobin , type 2 diabetes , endocrinology
Background Diabetic children treated with intensive insulin therapy are showing a dangerous increase in severe hypoglycemic episodes. The Continuous Glucose Monitoring System (CGMS) allows glycemic profiles to be monitored over a 72‐h period. The aim of the present study was to evaluate whether this system is sufficiently sensitive to detect asymptomatic hypoglycemia, and to determine if its periodic application would help to minimize the hypoglycemic risk in children with type 1 diabetes mellitus (T1DM). Methods Twenty‐seven T1DM children (age range 6–13.1 years) were enrolled in the study. The sensor was inserted subcutaneously in each patient and the standard four or five registrations of capillary glycemia per day were performed. Eighteen patients continued in the study and the glucose sensor was again inserted after a 6‐week interval. At the beginning and end of the study, fructosamine, glycosylated hemoglobin (HbA 1c ), median glycemia, number and duration of hypoglycemic events and insulin requirement were evaluated. Results A significantly higher number of asymptomatic hypoglycemic events was revealed by CGMS in comparison with the standard system (3.6 ± 2.3 vs 0.7 ± 0.9; p < 0.0001). In patients who continued in the study, insulin therapy adjustments reduced the incidence of hypoglycemic events (2.5 ± 1.7 vs 3.9 ± 2.2; p < 0.05). At the 6‐week point, the fructosamine level was reduced (330 ± 30 vs 349 ± 24 µmol/l; p < 0.05). Conclusions The CGMS is a useful device not only for detecting unrecognized hypoglycemia, but also for modifying insulin therapy in order to reduce hypoglycemic events. The system appears to be useful in avoiding long exposure to hypoglycemia. Copyright © 2002 John Wiley & Sons, Ltd.